诊断学理论与实践

诊断学理论与实践 >

2021 , Vol. 20 >Issue 06: 540 - 546

DOI: https://doi.org/10.16150/j.1671-2870.2021.06.005

论著

磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究

展开
  • 1.南京中医药大学附属南京中医院放射科,江苏 南京 210022
    2.上海交通大学医学院附属瑞金医院,a.放射科,b.核医学科,c.血液科,上海 200025

收稿日期: 2021-05-06

  网络出版日期: 2021-12-25

收起

Comparison of magnetic resonance whole body diffusion weighted imaging with FS-T2WI and FDG-PET/CT for initial staging and detection of lesion in newly diagnosed lymphoma

Expand
  • 1. Department of Radiology, Nanjing Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Jiangsu Nanjing 210022, China
    2a. Department of Radio-logy; 2b. Department of Nuclear Medicine; 2c. Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University of Medicine, Shanghai 200025, China

Received date: 2021-05-06

  Online published: 2021-12-25

Fold

摘要

目的: 比较磁共振全身扩散加权成像（whole body-diffusion weighted imaging,WB-DWI）结合T2WI抑脂序列（fat saturation T2-weighted imaging, FS-T2WI）及正电子发射计算机体层显像仪（positron emission tomography and computed tomography,PET/CT）在初发淋巴瘤分期诊断中的应用价值。方法: 回顾性分析2014年5月至2020年9月上海交通大学医学院附属瑞金医院血液科收治的初发、未经治疗且经病理证实的淋巴瘤患者25例,其中24例为非霍奇金淋巴瘤,1例为霍奇金淋巴瘤。患者分别行磁共振WB-DWI结合FS-T2WI序列及18F-氟代脱氧葡萄糖（18F-fluorodeoxyglucos,18F-FDG）PET/CT检查。以临床标准为金标准（由临床、病理、影像、骨髓穿刺及6个月随访结果综合分析,参照Ann-Arbor分期法）,比较2种检查方法在病灶的检出及分期间的一致性。结果: 采用PET/CT、磁共振WB-DWI结合FS-T2WI序列检查评估了500处淋巴结区域,其中有466处检出结果相同,2种检查方法对结内病灶的诊断差异无统计学意义（P>0.05）,具有较高的一致性（K=0.807）。采用PET/CT及磁共振WB-DWI结合FS-T2WI序列评估了450处结外脏器,其中有444处检出结果相同,2种检查方法对结外病灶的诊断差异无统计学意义（P>0.05）,具有较高的一致性（K=0.857）。25例患者中20例采用2种检查方法获得的分期相同,具有良好的一致性（K=0.731）。与临床分期相比,PET/CT检查低估了3例患者的分期,而磁共振WB-DWI结合FS-T2WI检查诊断此3例分期正确。磁共振WB-DWI结合FS-T2WI检查低估了2例患者的分期,而PET/CT检查诊断此2例分期正确。结论: 磁共振WB-DWI结合FS-T2WI序列扫描与FDG-PET/CT检查对初发淋巴瘤病灶的检出及分期间具有较好的一致性,而WB-DWI结合FS-T2WI序列扫描无电离辐射、无需注射对比剂,在淋巴瘤分期中可与PET/CT检查相互补充。

关键词： 全身扩散加权成像; 正电子发射计算机体层显像仪; 淋巴瘤; 分期诊断

本文引用格式

岳婧婧, 宋琦, 江旭峰, 王黎, 赵维莅, 严福华 . 磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究[J]. 诊断学理论与实践, 2021 , 20(06) : 540 -546 . DOI: 10.16150/j.1671-2870.2021.06.005

Abstract

Objective: To compare the application value of magnetic resonance whole body diffusion weighted ima-ging(MR WB-DWI) combined with FS-T2WI sequence and PET/CT in detection of disease lesion and staging in newly dia-gnosed lymphoma. Methods: A total of 25 patients with newly diagnosed lymphoma and without a history of treatment for lymphoma admitted to Department of Hematology in Shanghai Ruijin Hospital from May 2014 to September 2020 were retrospectively analyzed. All the patients were histologically confirmed, including 24 cases of non-Hodgkin lymphoma and 1case of Hodgkin lymphoma. MR WB-DWI with FS-T2WI and 18F-FDG PET/CT were performed and coincidence of results between the two techniques in lesion detection and disease staging were compared. The clinical criterion was taken as the gold standard (comprehensive analysis of clinical, pathological, imaging, bone marrow puncture and 6-month follow-up results, referring to Ann-Arbor staging method). Results: Results of WB-DWI with FS-T2WI in 466 node regions out of 500 areas were congruen with those of PET/CT (K=0.807, P>0.05), there were no significant difference between two techniques in detection of intranodal lesions. The two imaging techniques agreed on 444 organs out of 450 organs analyzed (K=0.857, P>0.05). The stages based on WB-DWI with FS-T2WI was concordant with those of PET/CT in 20 patients out of 25 patients (K=0.731, P>0.05). Compared with clinical stage, PET/CT underestimated disease stage in 3 cases and WB-DWI combined with FS-T2WI underestimated disease in 2 cases. Conclusions: WB-DWI combined FS-T2WI sequence have high consistency with 18F-FDG PET/CT in lesions detection and disease staging in newly diagnosed lymphoma, and could serve as a suppliment of PET/CT.

Key words： Whole body-diffusion weighted imaging; PET/CT; Lymphoma; Staging diagnosis

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013[J]. Chin J Cancer, 2017, 36(1):66.
[3] McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma[J]. Br J Haematol, 2020, 191(3):363-381.
[4] Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial[J]. Lancet, 2003, 362(9383):516-522.
[5] Pinilla I, Gómez-León N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma[J]. Q J Nucl Med Mol Imaging, 2011, 55(5):567-575.
[6] Robbins E. Radiation risks from imaging studies in children with cancer[J]. Pediatr Blood Cancer, 2008, 51(4):453-457.
[7] Mayerhoefer ME, Karanikas G, Kletter K, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients[J]. Clin Cancer Res, 2014, 20(11):2984-2993.
[8] 王燕, 宋琦. 磁共振全身弥散加权成像在淋巴瘤临床诊疗方面的应用价值及研究进展[J]. 诊断学理论与实践, 2019, 18(6):692-697.
[9] 王根杰, 田颖. 不同影像学方法在淋巴瘤分期诊断中的应用[J]. 中国CT和MRI杂志, 2019, 17(4):150-152.
[10] 沈俊杰, 张俊祥, 陈守康, 等. 3.0 T MRI类PET功能成像与PET/CT在淋巴瘤分期诊断中的对比研究[J]. 临床放射学杂志, 2017, 36(5):733-738.
[11] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27):3059-3068.
[12] 李莉, 强永乾, 任转琴, 等. 全身弥散加权成像在全身淋巴结病变中的应用价值[J]. 实用放射学杂志, 2013, 29(4):631-634.
[13] Spijkers S, Littooij AS, Humphries PD, et al. Imaging features of extranodal involvement in paediatric Hodgkin lymphoma[J]. Pediatr Radiol, 2019, 49(2):266-276.
[14] Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol, 2007, 25(5):571-578.
[15] Klenk C, Gawande R, Uslu L, et al. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study[J]. Lancet Oncol, 2014, 15(3):275-285.
[16] Regacini R, Puchnick A, Shigueoka DC, et al. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies[J]. Sao Paulo Med J, 2015, 133(2):141-150.
[17] Spijkers S, Littooij AS, Kwee TC, et al. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study[J]. Eur Radiol, 2021, 31(3):1494-1504.
[18] Kharuzhyk S, Zhavrid E, Dziuban A, et al. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging[J]. Eur Radiol, 2020, 30(7):3915-3923.
[19] Stéphane V, Samuel B, Vincent D, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression(DWIBS) for initial stagi-ng of malignant lymphomas[J]. Eur J Radiol, 2013, 82(11):2011-2017.
[20] Ferrari C, Minoia C, Asabella AN, et al. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma[J]. Hell J Nucl Med, 2014, 17(Suppl 1):40-49.
[21] Tsuji K, Kishi S, Tsuchida T, et al. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT[J]. J Magn Reson Imaging, 2015, 41(6):1601-1607.
[22] Tsushima Y, Takano A, Taketomi-Takahashi A, et al. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images[J]. Acad Radiol, 2007, 14(6):643-650.
[23] Spijkers S, Nievelstein RAJ, de Keizer B, et al. Fused high b-value diffusion weighted and T2-weighted MR ima-ges in staging of pediatric Hodgkin′s lymphoma: A pilot study[J]. Eur J Radiol, 2019, 121:108737.
[24] Baranska D, Matera K, Podgorski M, et al. Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT[J]. MAGMA, 2019, 32(3):381-390.
[25] Wang D, Huo Y, Chen S, et al. Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and sta-ging of lymphoma: a meta-analysis[J]. Onco Targets Ther, 2018, 11:3597-3608.
[26] Hong GS, Chae EJ, Ryu JS, et al. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients[J]. Cancer Imaging, 2021, 21(1):5.
[27] Asenbaum U, Nolz R, Karanikas G, et al. Bone marrow involvement in malignant lymphoma: evaluation of quantitative PET and MRI biomarkers[J]. Acad Radiol, 2018, 25(4):453-460.
[28] Wu LM, Chen FY, Jiang XX, et al. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis[J]. Eur J Radiol, 2012, 81(2):303-311.
[29] Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058.
[30] Tomizawa M, Shinozaki F, Uchida Y, et al. Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion and positron emission tomography/computed tomography of upper gastrointestinal cancers[J]. Abdom Imaging, 2015, 40(8):3012-3019.
[31] Stecco A, Buemi F, Quagliozzi M, et al. Staging of primary abdominal lymphomas: comparison of whole-body MRI with diffusion-weighted imaging and (18)F-FDG-PET/CT[J]. Gastroenterol Res Pract, 2015, 2015:104794.
Options
文章导航

/

〈 〉